S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ATRA Atara Biotherapeutics Inc

0.6845

-0.0055 (-0.80%)

After Hours

Last Updated: 06:10:45

Delayed by 15 minutes

Atara Biotherapeutics GAAP EPS of -$0.96 misses by $0.37, revenue of $7.55M misses by $27.59M

To read the full story on Seeking Alpha, click here.

Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Atara Biotherapeutics Charts.

Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Atara Biotherapeutics Charts.

Atara Biotherapeutics Inc News

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Saturday 6 April 2024 (4 weeks ago) • Business Wire

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Thursday 28 March 2024 (1 month ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Friday 1 March 2024 (2 months ago) • Business Wire

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Thursday 29 February 2024 (2 months ago) • Business Wire

Form 8-K - Current report
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Thursday 15 February 2024 (3 months ago) • Business Wire

More Atara Biotherapeutics Inc News Articles

JP Morgan Chase

Commonwealth Bank Of Aus...

Sterling vs AUD

Australian SE All Ordina...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions